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One Sentence Summary: Cloning, recombinant expression and characterization of human 
monoclonal antibodies that broadly neutralize multiple PML-causing JC polyomavirus variants.  
 
 
 
ABSTRACT 
In immunocompromised individuals, JC polyomavirus (JCPyV) may mutate and gain access to 
the central nervous system (CNS) resulting in progressive multifocal leukoencephalopathy 
(PML), an often fatal opportunistic infection for which no treatments are currently available. 
Despite recent progress, the contribution of JCPyV-specific humoral immunity to controlling 
asymptomatic infection throughout life and to eliminating JCPyV from the brain is poorly 
understood. Here, we examined antibody responses against JCPyV major capsid protein VP1 
variants in serum and cerebrospinal fluid (CSF) of healthy donors (HD), JCPyV-positive multiple 
sclerosis (MS) patients treated with the anti-VLA-4 monoclonal antibody natalizumab, and 
patients with natalizumab-associated PML. Prior to and during PML, CSF antibody responses 
against JCPyV VP1 variants show "recognition holes"; however, upon immune reconstitution, 
CSF antibody titers rise, then recognize PML-associated JCPyV VP1 variants and eliminate the 
virus. We therefore reasoned that the memory B cell repertoire of individuals who recovered 
from PML could be a source for the molecular cloning of broadly neutralizing antibodies for 
passive immunization. We generated a series of memory B cell-derived JCPyV VP1-specific 
human monoclonal antibodies from HD and a NAT-PML-IRIS patient. These antibodies 
exhibited diverse binding affinity, cross-reactivity with the closely related BK polyomavirus, 
recognition of PML-causing VP1 variants, and JCPyV neutralization. Interestingly, almost all 
antibodies with exquisite specificity for JCPyV, neutralizing activity, recognition of all tested 
JCPyV PML variants and high affinity were derived from one patient, who had recovered from 
PML. These antibodies are ideal candidates for the treatment of PML. 
 
 
 
INTRODUCTION 
JCPyV establishes life-long persistent infection of the kidney in a large fraction of the healthy 
population without known clinical consequences (1). During acquired or hereditary 
immunodeficiency such as AIDS, cancer, CD4 lymphopenia or monoclonal antibody therapy, 
archetypic JCPyV may acquire mutations. Whether these mutations are a prerequisite for CNS 
entry or occur in the CNS is not clear. Mutated JCPyV variants (JCPyVPML/GCN) either cause a 
lytic infection of glial cells or cerebellar granule neurons resulting in progressive multifocal 
leukoencephalopathy (PML) and granule cell neuronopathy (GCN), respectively (2-5). 
Immunomodulatory or -suppressive treatments with specific monoclonal antibodies including 
efalizumab, rituximab and particularly natalizumab have been shown to increase risk for 
PML/GCN, underscoring that JCPyV infection of the CNS may occur when immune surveillance 
by virus-specific T cells and/or antibodies is perturbed (5-8). Both PML and GCN may be fatal if 
the underlying immune suppression is not resolved.  
To overcome PML, measures to boost general immune competence such as infusion of 
recombinant IL-2 (9) and IL-7 (10, 11), administration of polyvalent intravenous 
immunoglobulins (12) as well as the infusion of JCPyV-specific cytotoxic T cells (13) and a 
combination of active vaccination with JCPyV VP1 and recombinant IL-7 (14) have been applied 
and shown promise. These data together with the abovementioned studies indicate that specific 
immune recognition by T cells and antibodies are critical for terminating PML. In patients with 
AIDS and also in natalizumab-associated PML restored CD4+ T cell function and recovering 
immune surveillance of the CNS after natalizumab washout can lead to a so-called PML immune 
reconstitution inflammatory syndrome (IRIS), which is characterized by massive infiltration of T 
and B cells leading to prominent inflammation of the JCPyV-infected CNS tissue that efficiently 
eliminates JCPyV, but often also results in acute neurological deterioration, additional brain 
damage, and can even lead to death of the patient due to tissue swelling (15-18).  
Attempts to treat PML with antivirals, mefloquine and mirtazapine have all failed (19), and no 
effective therapy is currently available. Observations from AIDS patients, who can recover from 
PML once CD4+ numbers and virus-specific IgG titers rise under antiretroviral therapy (5, 7) and 
also data from PML in natalizumab (NAT)-treated MS patients, who eliminate JCPyV once the 
anti-VLA4 monoclonal antibody has been washed out, suggest that regaining 
immunocompetence and allowing JCPyV-specific T cells access to the brain are critical factors to 
recover from PML. According to immunological studies JCPyV-specific CD8+, CD4+ T cells, 
and associated with the latter also JCPyV-specific IgG titers have been implicated in recovery 
from PML (6-8, 17), although the specific contributions of each component of the adaptive 
immune system are not fully understood. 
PML incidence steadily declined in HIV-infected individuals with the introduction of 
antiretroviral therapy, but emerged as a major medical concern during monoclonal antibody 
therapy, particularly in natalizumab-treated MS patients (5). More than 560 PML cases have been 
reported (20). In more than 20% of patients PML was fatal, and in a large fraction it led to severe 
residual neurological deficits (21). Both in AIDS patients and in NAT-associated PML, the major 
capsid protein of JCPyV VP1 has been identified as most important target antigen for CD4+ and 
CD8+ T cells in several studies (17, 22-24). While the role of JCPyV-specific antibodies has 
remained less clear, the abovementioned data indicate that CD4+ T cell numbers and function and 
JCPyV-specific IgG titers correlate with recovery from PML in AIDS patients (7). In NAT-
treated MS patients risk stratification strategies have been based on prior exposure to 
immunosuppressive drugs, length of NAT treatment as well as JCPyV-specific antibody indices 
(25, 26). Approximately 54% of MS patients are JCPyV-seropositive (26-28). Both serum 
JCPyV-specific antibody levels and intrathecal JCPyV-specific antibody production are increased 
in patients at onset of NAT-associated PML (28, 29). The latter finding and the fact that pre-PML 
samples revealed sustained higher anti-JCPyV antibody indices over time (26) questions the role 
of JCPyV-specific antibodies in the prevention of PML development and clearance of JCPyV 
infection from the brain. However, no data are available on functional aspects of JCPyV-specific 
antibodies regarding neutralization, affinity and target epitopes, and neither for healthy subjects, 
MS patients nor in PML patients.  
Besides the quality and quantity of the adaptive immune response of the infected host, 
characteristics of the virus play an important role in PML. Archetypic or wild type (WT) virus, 
which causes life-long, clinically inapparent infection of the epithelial cells in the kidney and 
urinary tract, has to undergo mutations in order to be able to cause PML (30). PML-associated 
JCPyV genotype variants show characteristic mutations of VP1 and rearrangements of the non-
coding regulatory region (NCCR), which are probably responsible for preferential tropism for 
glial cells or neurons and propagation in the CNS (31-33). Furthermore, rearranged NCCRs 
constitutively activate early gene expression and increase viral replication rate (34). It is not 
known, however, whether mutations of VP1 of PML-causing JCPyV variants influence the 
immune surveillance of JCPyV VP1-specific antibodies.  
Based on the above considerations, it is highly desirable to establish prophylactic and therapeutic 
immunization regimens in order to avoid the onset of PML or eliminate the virus, once it has 
infected the CNS. Such active and passive vaccinations should either stimulate protective 
adaptive immunity or, in the case of ongoing PML, be administered as a treatment. In patients 
with underlying hereditary or acquired immunodeficiency, we reasoned that active immunization 
with JCPyV VP1 may only be effective if combined with measures that allow a certain degree of 
immune reconstitution. Our recent data from compassionate use vaccinations of PML patients 
with idiopathic CD4 lymphopenia or immunodeficiency after cancer and stem cell transplantation 
support this rationale (14). Administration of human recombinant IL-7 as globally immune 
reconstituting agent combined with active immunization using JCPyV VP1 and a toll-like 
receptor 7/9 agonist as adjuvant (imiquimod) led to clearance of JCPyV from the CNS and 
recovery from PML (14). However, active immunization with JCPyV VP1 may only be effective 
if the patient either has residual immune function or if the latter is restored by cytokines like IL-7 
and IL-2 (9-11). If JCPyV-specific antibodies play a role in neutralizing free infectious virions 
and/or clearing the virus from the CNS during PML, we assumed that the therapeutic 
administration of JCPyV-specific antibodies, i.e. passive vaccination, may be an effective and 
safe measure that could immediately be applied, once PML has been diagnosed. Support for this 
assumption stems from a third patient with idiopathic CD4 lymphopenia, whom we successfully 
vaccinated with JCPyV VP1/VLP, imiquimod and recombinant IL-7 as previously shown (14). In 
this patient, the JCPyV-specific antibody response not only rapidly increased following 
vaccination and broadened with respect to recognition of PML variants including the one 
infecting the patient, but in parallel to the increasing antibody response the patient's CSF JCPyV 
viral load declined to zero (35).  
The present study aimed at developing a better understanding of the biological role of JCPyV-
specific antibodies in the onset/termination of PML. Further, we speculated that NAT-treated MS 
patients, who developed PML and following IRIS eliminated the virus, should harbor antibodies 
that are suitable for passive vaccination. For this purpose we evaluated the antibody response in 
serum and CSF of HD, NAT-treated MS patients, NAT-PML and NAT-PML-IRIS patients 
against various JCPyV VP1 variants, in order to identify individuals for the molecular cloning of 
JCPyV-specific human monoclonal antibodies from memory B cells after recovery from PML. 
We characterized 30 human JCPyV VP1-specific monoclonal antibodies with respect to 
functionality and specificity profile and selected antibody candidates for the treatment/passive 
immunization of PML patients or patients at risk for PML. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS  
Humoral immune response against JCPyV VP1 variants is compromised in PML 
We developed a capture enzyme-linked immunosorbent assay (ELISA) using recombinant 
JCPyV VP1 variants including the prototypic neurovirulent MAD1 strain, a kidney isolate strain 
(WT3), as well as three of the most frequently occurring PML-associated VP1 variants harboring 
the mutations L55F, S267F or S269F in the background of VP1MAD1 (36, 37). Equivalence in 
purity and quantity of the recombinant VP1 proteins was demonstrated by gel electrophoresis 
(Fig. 1A). A HD serum was selected as reference standard with equivalent concentration-
dependent binding to all VP1 variants (Fig. 1B). Screening using VP1MAD1 revealed an increase 
of anti-JCPyV VP1 antibodies in serum of NAT-PML patients and even higher levels in NAT-
PML-IRIS patients, compared to healthy subjects (HD) and JCPyV-seropositive MS patients 
under natalizumab treatment (NAT)(Fig. 1C; demographics in Table 1), consistent with a 
previous report (28). Sera were further analyzed for binding activity to VP1 variants following 
normalization to their response against prototypic MAD1. Responses varied widely between 
individuals (Fig. 1D). The average reactivity to VP1WT3 did not differ between groups and was 
similar to responses against VP1MAD1. In contrast, reduced serum responses against the PML-
associated variant VP1L55F were observed in NAT-PML, indicating compromised immune 
recognition. Interestingly, both serum antibody responses to variants L55F and S269F are lower 
in JCPyV-seropositive NAT MS patients (Fig. 1D). The JCPyV variant VP1S267F is poorly 
recognized by all groups suggesting that the S267F mutation affects an immunodominant epitope 
that is targeted by a large fraction of the JCPyV VP1-specific antibody repertoire. Recognition 
patterns of individual NAT-PML patients varied from robust humoral responses against all 
variants (e.g. patient 4), patients with stronger recognition against one VP1 variant but lower 
response to others (e.g. patients 8 and 12) to patients with low responses to all PML-associated 
mutations (patients 7 and 13) (Fig. 1E).   
 
Immune reconstitution leads to broadened antibody responses against PML-causing JCPyV 
VP1 variants  
It is important to note that the serum antibody responses against VP1L55F and VP1S269F increased 
during immune reconstitution (NAT-PML-IRIS) (Fig. 1D). Intrathecal JCPyV VP1-specific 
antibody titers also increased upon immune reconstitution from NAT-PML to NAT-PML-IRIS 
(Fig. 2A). While intrathecal antibodies against VP1L55F are lower compared to MAD1 in NAT-
PML patients, similar to what we observed in serum, these responses increased and were higher 
in NAT-PML-IRIS patients (Fig. 2B). Since the above analysis, which compares the antibody 
response against JCPyV VP1 variants to VP1MAD1, does not allow us to judge whether antibodies 
are synthesized at higher levels within the CSF compared to serum, we assessed the intrathecal 
antibody production against different JCPyV VP1 proteins. In line with a previous report (28), 
approximately half of the NAT-PML patients (6 out of 14) showed signs of intrathecal antibody 
production (CAIJCPyV>1.5) against both JCPyV VP1MAD1 and VP1WT3 (Fig. 2C, left and second 
panel from left). We then extended this analysis to the JCPyV PML variants, and again a 
substantial fraction of NAT-PML patients showed intrathecal antibody responses against all three 
mutant VP1 proteins (Fig. 2C middle, second from right and right panels). Most important in the 
context of this study, the intrathecal antibody responses against all VP1 proteins (MAD1, WT3 
and mutant proteins) increased by tenfold or more during NAT-PML-IRIS in 7 of 8 patients 
indicating a high-titer and broad antibody response directed against multiple variants within the 
CNS compartment upon immune reconstitution.   
 
Generation and characterization of human monoclonal antibodies against JCPyV reveals 
different binding properties 
The above data indicate that our original assumptions were likely correct in that patients who 
eliminated JCPyV from the CNS compartment following PML-IRIS mount robust and broad 
antibody responses against several JCPyV VP1 proteins including non-pathogenic JCPyV 
archetype (WT3), prototypic PML variant MAD1 and frequent VP1 PML-causing mutations. The 
observation that the antibody responses are even stronger in the CNS compartment than in the 
serum further hints at their biological relevance. We therefore selected a NAT-PML-IRIS patient 
(for patient information see supplementary materials), who had successfully controlled PML and 
showed strong antibody responses to JCPyV VP1. From this individual and selected HD we 
isolated memory B cells expressing VP1-specific antibodies with the aim to identify broadly 
neutralizing antibody lead candidates for passive immunization. 
As expected based on seroprevalence in the general population we could identify B cells 
expressing antibodies binding to JCPyV VP1 VLPs from most of the healthy donors (HD) (27 
out of 40). The frequency of JCPyV VP1-reactive memory B-cells was increased by more than 
10-fold in the NAT-PML-IRIS patient suggesting an efficient antibody response. We cloned and 
recombinantly expressed 30 human-derived monoclonal antibodies (10 from HD and 20 from the 
NAT-PML-IRIS patient) and characterized their binding affinities towards JCPyV and BKPyV 
VP1 VLPs and their specificity to intact or denatured VLPs. 
The majority of the antibodies from the NAT-PML-IRIS patient showed extremely high affinity 
for the JCPyV VP1 VLPs with a half-maximal binding (EC50) down to the femtomolar range 
(Fig. 3A) and weak or no binding to BKPyV VP1 VLPs. Interestingly, those antibodies were only 
able to recognize intact VLPs and did not show binding to denatured VLPs on ELISA or on 
Western blot following denaturing SDS-PAGE, suggesting the targeting of conformational 
epitopes specific to the JCPyV VP1 capsid (Fig. 3A). 
A second class of antibodies showed similarly high affinity to JCPyV but also to BKPyV VP1 
VLPs with EC50 in the low picomolar range. These antibodies also only bound to intact VLPs and 
did not recognize any linear epitope. Thus, we classified this second category as antibodies that 
specifically recognize JCPyV and BKPyV VP1 VLPs with high affinity and target a 
conformational epitope that is shared by the capsids of both viruses (Fig. 3B). 
In contrast to the antibodies from the NAT-PML-IRIS patient antibodies from HD displayed a 
wide range of binding affinities with EC50 values to the low picomolar range. They did not 
discriminate between intact and denatured VLPs by ELISA and recognized JCPyV as well as 
BKPyV VP1 proteins. These data suggest a profound difference in the memory B cell repertoires 
in HD versus NAT-PML-IRIS with the majority of antibodies generated by HD targeting linear 
epitopes that are mostly shared between JCPyV and BKPyV (Fig. 3C). 
 
Human JCPyV-specific monoclonal antibodies inhibit JCPyV infection in vitro  
To assess the neutralizing ability of the recombinant human-derived monoclonals, we established 
an infection assay using JCPyVMAD4 strain infection of the human fetal astrocyte-derived glial 
cell line SVG-A (Fig. 4, top middle panel). Antibodies that were previously determined to target 
a conformational VP1 capsid epitope completely abolished JCPyV infection whereas antibodies 
recognizing linear epitopes did not, comparable to an unrelated isotype control antibody (Fig. 
4A). While only one of the antibodies cloned from HD was capable of blocking JCPyV infection, 
the majority of antibodies (18/20) cloned from the PML-IRIS patient showed complete 
neutralization of the viral infection (Fig. 4B, right graph). 
 
Human monoclonal antibodies show crossreactivity against multiple JCPyV VP1 variants 
The structure of JCPyV VP1 highlights three exterior loops at the outer surface of the JCPyV 
capsid, which are in principle accessible as epitopes for VP1-specific antibodies (Fig. S1). 
Interestingly, the most common PML-associated mutations such as L55F, S267F and S269F are 
located in several of these loops (Fig. S1), which are involved in host receptor binding (36) 
explaining why these mutations from an aliphatic to an aromatic (L55F) or a relatively small 
polar (S) to a large aromatic amino acid (F) in positions 267 and 269 have such an impact on 
antibody recognition. We therefore tested the monoclonal antibodies for binding to the respective 
VP1 mutants by ELISA. In line with the above data on serum and CSF antibodies, we confirmed 
at the level of the individual monoclonal antibody that most of the VP1-specific antibodies bound 
with reduced affinity or even completely failed to recognize some of the VP1 variants in 
comparison to VP1MAD1 (Fig. 5A). The observed reduction in antibody binding was independent 
of the affinity established for JCPyVMAD1 VLP. Consistent with the much weaker recognition of 
VP1S267F by serum and CSF antibodies in HD and patients, binding to S267F seemed to be 
affected in the majority of antibodies derived from the NAT-PML-IRIS patient, however, 
absence of antibody recognition was observed also for other VP1 variants in some monoclonals. 
The observation that the mean responses of the NAT-PML-IRIS patient-derived antibody 
responses closely match with the autologous serum response underscores that the memory B 
cells, which had been picked for generation of the monoclonal antibodies, reflected the humoral 
immune response in vivo (Fig. 5B). Interestingly, during NAT-PML-IRIS several antibodies 
developed with increased binding to some VP1 variants compared to MAD1, in particular to 
VP1S269F (Fig. 5B). Reduced antibody binding to some of the VP1 variants was also observed in 
HD-derived monoclonal antibodies, but less pronounced than in the NAT-PML-IRIS patient (Fig. 
5C). This is probably due to the much higher affinities of the NAT-PML-IRIS-derived antibodies. 
Non-neutralizing antibodies (e.g. 72F7, 43E8 and 8 of 9 HD-derived antibodies) were less 
affected in their recognition of VP1 variants, indicating that epitope binding of these antibodies 
most probably occurs outside of the mutation-associated exterior loops of VP1. 
Regarding the overall goal of our study, it is most important that we identified five monoclonal 
antibody candidates (27C11, 47B11, 26A3, 50H4 and 98H1) derived from the NAT-PML-IRIS 
patient, which not only revealed high affinity to JCPyV VLP and potent neutralization capacity, 
but also very efficient recognition all five VP1 variants. Furthermore, we could also demonstrate 
this broad binding to additional VP1 variants with mutations located within the exterior loops 
(e.g. VP1N74S, VP1R75K, VP1T117S) by using a complementary approach with pCAG-JCPyV -
transfected cells (38) combined with intracellular staining (Fig. S2). 
Based on the established binding profiles of the monoclonal antibodies, we tested whether the 
broadly recognizing antibodies target shared or independent binding regions. Towards that end, 
we performed competition experiments assessing whether selected antibodies could recognize 
JCPyV VLPs following saturation with the antibody 98D3. While antibody 72F7 displayed an 
unaltered binding profile, antibodies 27C11, 47B11, 26A3, 50H4 and 98H1 were unable to bind 
to the 98D3-bound VLPs suggesting that they target the same binding pocket in JCPyV VP1 
whereas the non-neutralizing 72F7 antibody binds to a distinct epitope (Fig. S3). It is, however, 
unlikely that these antibodies bind to the exact same amino acid residues since they are showing 
different recognition profiles of PML-associated VP1 mutants. 
Further characterization of the antibodies with respect to their sequence revealed that at least 10 
of 20 IGH clones isolated from the PML-IRIS patient originated from different germline 
sequences (Table 2). This indicates that a broad spectrum of B cell clones is involved in 
mounting a JCPyV-specific humoral immune response with a variable degree of affinity to 
JCPyV VP1 variants and neutralization and cross-recognition of JCPyV VP1 variants and wild-
type BKPyV VP1 (Fig. 6). Amongst all these recombinant antibodies, a subgroup of evolutionary 
convergent antibodies (98H1, 50H4, and 27C11) represent highly promising candidates for the 
development of a broadly neutralizing passive immunotherapy against JCPyV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
The occurrence of PML in diseases like SLE, during immunomodulatory treatments, which affect 
B cells (5, 6), and in immunodeficiencies that primarily involve antibodies, i.e. Franklin disease 
(39), or B cells/antibodies and T cells, i.e. Good's syndrome (40) and hyper IgE syndrome (41), 
indicates that not only T cells, but also B cells are possibly involved in the development of PML. 
Natalizumab compromises CNS immune surveillance by reducing the migration of T cells, 
CD19+ B cells and CD138+ plasma cells through the blood-brain-barrier (42), but also perturbs 
peripheral B cell niches by increasing the number of memory- and marginal zone-like B cells 
(43). The release of CD34+ progenitor cells into the peripheral blood may favor the evolution and 
reactivation of neurotropic JCPyV variants (44, 45). Rituximab depletes CD20+ B cells and 
perturbs B cell homeostasis (5, 46), however, it is currently unknown, if the B cell depletion by 
rituximab results in PML because of reduced antibody responses against JCPyV, which is less 
likely, or perturbation of other B cell functions such as antigen presentation to T cells (47). 
Hence, B cells could be involved at multiple steps of PML development from viral mutation to 
PML variants, and transport of glial/neurotropic JCPyV variants into the CNS, and both the 
underlying disease, e.g. HIV/AIDS or idiopathic CD4 lymphopenia, or specific immune 
interventions such as natalizumab or chemotherapy can probably contribute. 
Regarding their protective function several, albeit mostly indirect, lines of evidence indicate that 
B cells and JCPyV-specific antibodies play a role. These include the observations that IgG 
responses and CD4+ T cell counts positively correlate with survival in HIV/AIDS patients (7) and 
that CD19+ B cells, CD38+ plasmablasts and CD138+ plasma cells are found in the immune cell 
infiltrate in the brain of PML-IRIS and GCN-IRIS patients (17, 18, 48). Further support stems 
from the analysis of the T cell infiltrate in the brains of PML-IRIS and GCN-IRIS patients (17, 
48). During IRIS CD4+ T cells with a T helper 1/2 phenotype, i.e. cells that secrete both 
interferon-γ and interleukin-4, which is important to mount B cell responses, are particularly 
prevalent, and it is of interest to note that the vast majority of these are directed against JCPyV 
VP1 epitopes (17, 49). Consistent with previous data (26, 28) we found an increase of JCPyV-
specific antibodies in the serum when PML occurs. Probably more importantly, intrathecal 
JCPyV-specific antibody titers strongly rise and are considered as diagnostic evidence of ongoing 
PML in patients with clinical findings compatible with PML and at the same time low or absent 
JCPyV DNA in the CSF, which is not rarely the case, when IRIS has begun (12, 17, 28). Finally, 
the rise in CSF anti-JCPyV antibodies with specificity against several PML variants including the 
one found in the CSF in a patient following vaccination with JCPyV VP1/VLP (35) argues that a 
B cell/antibody response in the CNS compartment plays an active role in containing and/or 
eliminating the virus. 
JCPyV VP1-specific antibody responses in the serum are used for risk stratification of patients 
that are treated with natalizumab (25). Interestingly, patients with intermediate antibody indices 
have a much lower risk to develop PML, while those with high indices show an elevated risk 
(26). It is currently not clear if this unexpectedly higher PML risk in the presence of higher anti-
JCPyV VP1 antibody titers indicates that antibodies are functionally deficient, i.e. not capable of 
neutralizing the virus, or if they are directed against the VP1 that is used in the assay (MAD1 
strain) but fail to bind other relevant mutant strains. Regarding risk stratification it has been 
shown that JCPyV viremia was observed in patients seronegative for anti-JCPyV VP1 antibodies, 
indicating that testing JCPyV-specific antibodies might not be sufficient to assess the status of 
JCPyV infection in natalizumab-treated MS patients (50). Our data show that VP1 mutations of 
JCPyV probably play a critical role in determining whether a humoral response is protective or 
not. JCPyV VP1 mutations are frequently found in addition to prototype MAD1 sequences in the 
CNS of PML patients (32, 33). In contrast to archetypic JCPyV strains that are excreted in the 
urinary tract, PML-associated JCPyV genotypes present characteristic mutations of VP1 and 
rearrangements of the non-coding regulatory region, which probably allow entry to and 
propagation in the CNS as well as preferential tropism for glial cells or neurons (3, 31, 32). Up to 
date it is not clear whether PML-associated alterations of the JCPyV genome occur inside or 
outside of the CNS, and which mechanisms contribute to their occurrence or selection (32, 33, 
45). Besides influencing cellular tropism and CNS invasion, the individual heterogeneity in 
serum and CSF antibody responses against the most frequently found JCPyV VP1 mutations at 
positions 55, 267 and 269, however, indicate that antibody “recognition holes” likely play a role 
in PML. This notion is supported by data of Ray et al. (35) showing that PML patients fail to 
produce antibodies recognizing their "own" PML mutant. Particularly JCPyV VP1L55F and 
VP1S267F are recognized less well by sera and CSF in NAT-PML patients, and, while the 
responses to JCPyV VP1L55F rise at NAT-PML-IRIS, recognition of VP1S267F remains lower. 
Despite strong intrathecal antibody responses already during NAT-PML and further increase in 
NAT-PML-IRIS against all tested JCPyV VP1 variants, the response to VP1S267F remains weaker 
compared to JCPyV VP1MAD1.  
The above data indicate that JCPyV-specific antibodies play an important role in controlling 
JCPyV infection and probably also in containing and eliminating virus from the brain once PML 
has developed. In MS patients a recent proof-of-concept study demonstrated that 29% of sera 
from MS patients lack anti-JCPyV neutralizing activity despite the presence of anti-JCPyV VP1 
antibodies (51). Hence, the functional properties of JCPyV antibodies, i.e. their neutralizing 
activities, and their breadth regarding recognition of multiple JCPyV PML variants may 
determine how well infection with JCPyV is controlled. 
Natalizumab remains one of the most effective and generally very well tolerated therapies, but 
the impaired immune surveillance of the CNS leads to a PML risk between 1/100-1/1000 or even 
higher for patients, who have been treated for longer than 2 years and after prior 
immunosuppression (25). Once PML occurs, immune surveillance is restored after antibody 
washout by plasmapheresis, and when NAT-PML-IRIS begins, JCPyV-infected cells are 
recognized by virus-specific CD4+ and CD8+ T cells with preferential specificity for JCPyV VP1 
and the strong intrathecal JCPyV VP1-specific antibody response (17). NAT-PML-IRIS carries 
the risk of too vigorous immune responses with subsequent brain damage and clinical worsening 
up to death from acute brain swelling. From these reasons and different from patients with 
underlying immunodeficiencies or compromised immune function, active immunization with 
JCPyV VP1, for which we recently provided promising preliminary data in immunocompromised 
patients (14), would not be indicated or at least carry substantial risk. However, a treatment with 
anti-JCPyV VP1-specific antibodies could be applicable to all patients with PML immediately 
following their diagnosis, with a significantly lower expected risk of clinical liabilities including 
IRIS, although high doses of antibody may be needed due to the limited access of antibodies 
through the blood-brain- and blood-CSF barriers. Furthermore, since almost all NAT-PML-IRIS 
patients are capable of eliminating JCPyV from the CNS and recover from PML, we assumed 
that they would represent an ideal resource for the generation of recombinant therapeutic 
antibodies with ideal drug-like properties combining high affinity targeting of the VP1 capsid, 
biological neutralization activity and a broad cross-recognition of clinically relevant JCPyV PML 
variants. The molecular engineering technology applied to generate the human-derived antibodies 
preserves the favorable immunobiological features of the human antibody response, including 
epitope selection, affinity maturation, and tolerance mechanisms creating a set of optimized drug 
candidates with optimal biophysical, pharmacological and safety properties. When we compared 
the memory B cell repertoires from both HD and a NAT-PML-IRIS patient using JCPyV and 
BKPyV VLPs we were surprised to find that the human antibodies cloned from HD, i.e. during 
the state of persistent JCPyV infection of the kidney, are of relatively low affinity, are cross-
reactive with BKPyV and that only one of the antibodies had neutralizing activity. In contrast, the 
antibodies cloned from the NAT-PML-IRIS patient were with few exceptions high affinity, many 
showed broadly neutralizing activity and were highly specific for JCPyV VP1 but failed to 
recognize BKPyV VP1. This is in agreement with sequence differences between the BKPyV and 
JCPyV VP1 pentamers, which mostly map to surface-exposed loops that display mutations in 
PML and that would be likely targets for antibody neutralization (Fig. S4).  
Regarding antibody function, few data are currently available, however, the IgG subclass 
distribution in the CSF of two patients with natalizumab-associated PML-IRIS, who recovered 
well from the infection (17), showed that IgG1 and IgG3 were most prominent, which may 
indicate in addition to direct virus neutralization a role also of effector functions including 
opsonization, complement activation, phagocytosis, and/or antibody-dependent cellular 
cytotoxicity. It is also not clear if anti-JCPyV antibodies act primarily by neutralizing 
extracellular virions or also intracellularly in infected cells or by inhibiting binding of the mutant 
viruses to an as yet unknown receptor, which is different from the glycan receptor LSTc and in 
particular to the sialic acid moiety of that receptor (52). The latter point is supported by the fact 
that infection of oligodendrocytes and astrocytes during PML has been proposed to be LSTc 
independent (53). Antibodies against intracellular and even nuclear epitopes are, however, well 
documented in autoimmune diseases (54), and a recent study showed that the intracellular 
antibody receptor, tripartite-motif protein 21 (TRIM21), a ubiquitously expressed E3 ubiquitin 
ligase provides a mechanism to protect mice from lethal adenoviral infection via intracellular 
antibody recognition (55). Hence, JCPyV-specific antibodies may contribute to both extracellular 
and intracellular mechanisms in PML. 
Consistent with our above assumptions, a biologically different antibody repertoire had been 
generated during PML and subsequent PML-IRIS. Considering the reduced recognition of 
JCPyV PML variants VP1L55F and VP1S267F and generally the lack of recognition of different 
JCPyV VP1 variants (Fig. 1E) by serum antibodies of HD and NAT-PML patients, we defined a 
set of criteria for the selection of lead antibody candidates for future therapeutic development as 
a) recognition of conformational capsid epitopes of a broad spectrum of JCPyV VP1 PML 
variants, b) high binding affinity, and c) biological activity in neutralization of JCPyV infectivity.  
27C11 represents the most promising human-derived monoclonal that was identified in the 
present study. It  shows low picomolar affinity, neutralizing activity, equivalent recognition of all 
JCPyV VP1 variants examined in Fig. 5A, and beyond these also recognizes cells transfected 
with the pseudoviral constructs (pCAG-VP1) of VP1 variants VP1N74S, VP1R75K, VP1T117S, 
VPNGCN (Fig. S2).  
We did not find other examples of CNS infections, where broadly neutralizing antibodies 
developed during the course of infection, however, such antibodies arise in HIV-infected 
individuals independent of their germline repertoire (56) and are characterized by long heavy 
chain complementarity determining regions 3, polyreactivity and high levels of somatic 
mutations (57), which is also the case for the antibodies described here. 
Limitations of the present study include the moderate number of PML and PML-IRIS patients 
studied, that neutralization was only shown against infection with a prototypic JCPyV PML 
strain, although broad recognition of the most prevalent JCPyV PML strains has been tested with 
different methods, and the limited understanding of the contribution of the humoral immune 
response and anti-JCPyV antibodies during PML and the exact mechanism of action, i.e. whether 
they act primarily extracellularly and inhibit propagation of infection, or also have antiviral 
effects intracellularly in infected cells. Proof-of-concept clinical testing will hopefully shed light 
on this point. However, together with our promising data on active vaccination with JCPyV VP1 
(14, 35), the above findings provide insight about the role of the humoral immune responses 
during PML and lay the foundation for the development of targeted immunotherapy for PML 
with a newly identified class of broadly neutralizing human recombinant monoclonal antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Study design 
This study was a non-randomized laboratory study designed to investigate the antibody responses 
in serum and CSF in healthy subjects and patients with MS, PML or PML-IRIS and to 
recombinantly clone and characterize human-derived antibodies targeting JCPyV VP1 for the 
further development towards a treatment of PML. A newly developed JCPyV VP1 pentamer 
ELISA was used to evaluate humoral responses against PML-associated JCPyV variants in serum 
and CSF samples. JCPyV-specific human monoclonal antibodies were then cloned from memory 
B cells of selected HD and a NAT-PML-IRIS patient, who had recovered from PML, and further 
investigated regarding their affinities, specificities and functional properties using 
BKPyV/JCPyV VLP ELISA, Western Blot, JCPyV VP1 pentamer ELISA, FACS analysis of 
transfected VP1 variants as well as a JCPyV neutralization assay. Sample size was dictated by 
rate of sample collection (generally 2-5 ml serum, 5-10 ml CSF, 50-80 ml of peripheral blood for 
isolation of PBMCs), and blinding was not used. 
 
Study subjects 
Peripheral blood of patients with MS under natalizumab, natalizumab-associated PML, and PML-
IRIS and matched healthy controls, as well as CSF samples from natalizumab-associated 
PML/PML-IRIS were obtained after written informed consent of patients and approval by the 
Cantonal Ethical Committee of Zürich, Switzerland (EC-ZH-No. 2013-0001). MS patients under 
natalizumab therapy were all seropositive for JCPyV antibodies (Unilabs). Demographic data of 
all donors are shown in table 1. Samples at onset of PML-IRIS were obtained from the 
corresponding PML cases after washout of natalizumab and clinical as well as radiological signs 
of IRIS. Peripheral blood was used to collect serum and peripheral blood mononuclear cells 
(PBMCs) for isolation of memory B cells. 
 
Cells and virus 
SVG-A (transformed human fetal astrocytes, kindly provided by R. Girones, University of 
Barcelona, Spain) and HEK 293TT (human embryonal kidney cell line, kindly provided by C. 
Buck, Center for Cancer Research, NIH, USA) cell lines were cultured in suitable culture 
medium according to recommendations of ATCC. The JCPyVMAD4 strain (VR-1583™) was 
obtained from ATCC and propagated upon infection in SVG-A cells. Infectious supernatants 
were collected from productively infected SVG-A cultures with late-stage cytopathic effects, 
separated from cell debris by centrifugation and stored at -80°C. This strain is neurooncogenic 
and differs from MAD1 strain only by a 19 bp deletion in the regulatory region. 
 
JCPyV VP1 variant pentamer ELISA 
Purified recombinant JCPyV VP1 variant pentamers (provided by T. Stehle, University of 
Tübingen, Germany) (36) were preincubated with reassociation buffer (1 mM CaCl2 in TBS, pH 
7.6) before coating 100 ng of each VP1 variant pentamer per well of a 96-well microplate 
(Costar, Corning). After coating overnight at 4°C, plates saturated with a Casein-based blocking 
solution containing 1 mM CaCl2 at 37°C. Following wash steps, serial dilutions of standard 
serum, serum (1:404 and 1:2020 dilutions), CSF (1:2, 1:10, 1:100 and/or 1:1000 dilutions) or 
human monoclonal antibodies (100 pM, 1 nM and 10 nM dilutions) were added for 2 h at 37°C. 
Human IgG was detected using biotin-conjugated anti-human Fc antibody and horseradish 
peroxidase (HRP)-conjugated avidin (eBioscience). TMB single solution (Lifetechnologies) was 
used as colorimetric substrate for HRP and optical density at 450nm (OD450) was measured with 
a Synergy H1 microplate reader (BioTek). Antibody reactivity was assessed in arbitrary units 
(AU) using a standard curve obtained from a serial dilution of the respective standard serum for 
interpolating ODs by four parameter logistic curve fit. AUs within standard curve were 
multiplied by the corresponding dilution factor to obtain absolute AU. The JCPyV variant VP1-
specific CSF/serum antibody index (CAI VP1JCPyV) was calculated according to Reiber (58). 
Briefly, CAI VP1JCPyV was assessed as CAI VP1JCPyV = Qspec/QIgG, if  QLim > IgG, or  CAI 
VP1JCPyV = Qspec/QLim (IgG), if  QLim < IgG. The variables were calculated as follows:  Qspec = 
JCPyV variant-specific IgGCSF [AU]/JCPyV variant-specific IgGserum [AU]); QIgG = 
IgGCSF/IgGserum; QLim (IgG) = 0.93x (Qalb2 + 6x10-6 )0.5 –1.7x10-3.  Qalb = albCSF/albserum (with alb = 
albumin). QLim (IgG) refers to the upper discrimination line of the hyperbolic reference range for 
the blood-derived IgG in CSF as zero intrathecal IgG synthesis. Intrathecal antigen-specific 
antibody synthesis was defined as CAI VP1JCPyV ≥ 1.5. Data were analyzed using Microsoft 
Excel and GraphPad Prism 6. Heat maps were generated using Spice (NIH, NIAID) software. 
 
Memory B cell screening and molecular cloning of human antibodies 
Memory B cells were isolated from peripheral blood lymphocyte preparations and screened for 
the ability to bind to JCPyV VP1 VLPs. 96-well microplates (Costar) were coated overnight at 
4°C with VP1 or BSA (Sigma-Aldrich) diluted to a concentration of 1 µg/ml in reassociation 
buffer. Plates were washed in PBS-T pH 7.6 and non-specific binding sites were blocked for 1 h 
at RT with PBS/0.1% Tween-20 containing 2% BSA. Plates were incubated with B cell 
conditioned medium for one hour at RT, washed in PBS-T and binding was determined using 
HRP-conjugated anti-human immunoglobulins polyclonal antibodies (Jackson ImmunoResearch) 
followed by measurement of HRP activity in a standard colorimetric assay. Selected reactive B-
cell cultures were subjected to cDNA cloning of IgG heavy and kappa or lambda light chains 
variable region sequences, and sub-cloned in expression constructs using Ig-framework specific 
primers for human variable heavy and light chain families in combination with human J-H 
segment-specific primers. Functional recombinant monoclonal antibodies were obtained upon co-
transfection into HEK 293 or CHO cells of an Ig-heavy-chain expression vector and a kappa or 
lambda Ig-light-chain expression vector. Recombinant human monoclonal antibodies were 
subsequently purified from the conditioned medium using a standard Protein A column 
purification. VP1 antigens for recombinant full length JCPyV VP1 (strain MAD1) and BKPyV 
VP1 (strain AS) were purchased from Abcam. The antigen was incubated for 48 hours at 24°C 
with shaking in reassociation buffer to form the VLPs.  
 
JC and BK VLP ELISA 
ELISA assays were performed with varying antibody concentrations to validate the binding of the 
antibodies to JCPyV- or BKPyV-derived VP1 (Abcam) and to be able to determine their half 
maximal effective concentration (EC50). The ELISA was performed in 96-well microplates 
(Costar) coated overnight at 4°C with JCPyV or BKPyV VP1 VLPs solutions or BSA diluted to a 
concentration of 5 µg/ml in reassociation buffer. Non-specific binding sites were blocked PBS 
containing 2% BSA and 0.5% Tween20. Binding of human antibodies of the present invention 
was determined using a donkey anti-human IgG antibody conjugated with HRP (Jackson 
ImmunoResearch), followed by measurement of HRP activity in a standard colorimetric assay. 
EC50 values were estimated by a non-linear regression using GraphPad Prism. To determine the 
binding of the antibodies to the denatured VLPs, the 96-well microplates were coated overnight 
at 4°C with VP1 proteins diluted to a concentration of 5 µg/ml in carbonate buffer (15 mM 
Na2CO3, 35 mM NaHCO3, pH 9.42) and the ELISA was performed as previously described. 
 
Western Blot 
Recombinant VP1 proteins (1µg) from JCPyV and BKPyV were separated on a SDS-PAGE gel 
and then transferred onto nitrocellulose membranes. After blocking, the membrane was incubated 
with the human recombinant antibodies diluted to 1ug/mL in blocking buffer. After multiple 
washes, the secondary antibody (HRP-conjugated donkey anti-human IgG Fcγ only) was added 
and the membrane was then developed with ECL. The original blots are shown in Fig.S5. 
 
JCPyV neutralization assay 
To test the ability of the anti-VP1 antibodies to block the infection by JCPyV, we established an 
infection assay using the JCPyVMAD4 strain and the cell line SVG- A. 20,000 cells were seeded 
on a cover slip placed in a well of a 24-well tissue culture plate. After 15-24 h of incubation at 
37°C to allow cells to adhere to the surface of the cover slip, the JCPyVMAD4 strain was added to 
the well at the concentration necessary to achieve up to 10% infection. The viruses were allowed 
to adhere to the cells for 1 h at 37°C, and then cells were washed with PBS and cultured in fresh 
media at 37 °C to allow the infection to take hold. Infection of cells was determined 72 h post-
infection by fixation, permeabilization and labeling with a mouse JCPyV VP1-specific antibody 
(Abcam) and DAPI. Analysis of virus-containing cells was performed with a Zeiss Axiovert 
200M fluorescence microscope. Neutralization tests were performed by pre-incubating human-
derived JCPyV VP1-specific monoclonal antibodies (50 µg/ml) with the virus for 1 h at 37°C 
adding the mixture to the cells for 1 h at 37°C during viral attachment period. Infection of cells 
was determined in the presence and absence of human-derived anti-VP1 antibodies as well as an 
isotype control as described above.  
 
Sequence analysis and inference of germline ancestors 
Immunoglobulin heavy chain (IGH) sequences isolated from monoclonal antibodies from the 
NAT-PML-IRIS patient were identified by using IMGT/V-QUEST 3.3.2 (59). In particular, the 
most closely related germline sequences of variable (VH), diversity (DH) and joining (JH) heavy 
chain genes as well as the numbers of non-silent mutations was assigned to each clone by using  
IMGT/V-QUEST (Table 2). PML-IRIS IGH sequences were aligned by using ClustalW 
2.0.12 (60). Maximum parsimony lineage was inferred with the dnapars application online tool of 
PHYLIP v3.67 and an unrooted phylogenetic tree was constructed using Archaeopteryx 0.962 
beta 2N on the Pasteur Mobyle platform (61).  
 
Statistical analysis 
Statistical analyses were performed with GraphPad Prism. Data on antibody responses against the 
different VP1 pentamers were checked for normality (D`Agostino and Pearson omnibus 
normality test, α = 0.05). Data on serum responses against the JCPyV VP1 variants (Fig. 1C and 
1D) were tested with a nonparametric one-way ANOVA with Kruskal-Wallis test and Dunn 
multiple comparisons test (α = 0.05). Two-tailed Mann-Whitney U test was performed on data 
with CSF responses of NAT-PML and NAT-PML-IRIS (Fig.2A-C). P values are reported in the 
figure and figure legend where significant. 
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Fig. S1. Mutations in JCPyV viral capsid protein VP1.  
Fig. S2. Recognition of JCPyV VP1/VLP variants by human monoclonal antibodies.  
Fig. S3. Cross-competition assay of VP1-specific monoclonal antibodies. 
Fig. S4. Differences between JCPyV and BKPyV VP1. 
Fig. S5. Recognition of denatured JCPyV VP1 and BKPyV VP1 (Western Blot). 
Source data in tabular form (separate excel file) 
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Fig.1. VP1 mutations compromise serum antibody responses in natalizumab-associated 
PML. (A) SDS-PAGE of monomeric recombinant VP1 variants that were used as pentamers in 
ELISA. (B) Serial dilutions of a human standard serum with a high concentration of JCPyV VP1-
specific antibodies and equal recognition of all VP1 variants was used as a reference standard to 
estimate antibody binding expressed as arbitrary units (AU). (C) Serum antibody responses of 
healthy donors (HD), natalizumab-treated MS patients (NAT), natalizumab-associated PML 
patients (NAT-PML) and PML-IRIS patients (NAT-PML-IRIS) to VP1MAD1 pentamers, depicted 
in AU (Mean ± SEM). Statistically significant P values are shown for HD vs. NAT-PML-IRIS (n 
= 38; P = 0.0027, Kruskal-Wallis), HD vs. NAT-PML (n = 45; P = 0.0206, Kruskal-Wallis), 
NAT vs. NAT-PML-IRIS (n = 36; P = 0.0037, Kruskal-Wallis) and NAT vs. NAT-PML (n = 43; 
P = 0.0283, Kruskal-Wallis). (D) Relative binding of individual sera of the different donor 
populations to VP1 variants in comparison to VP1MAD1 (Mean ± SEM). Data from each donor 
was normalized to its corresponding recognition to VP1MAD1 set as 100% binding (red dotted 
line). Statistically significant P values are shown for HD vs. NAT-PML (n = 45; P = 0.0002, 
Kruskal-Wallis), NAT vs. NAT-PML-IRIS (n = 35; P = 0.0055, Kruskal-Wallis), NAT-PML  vs. 
NAT-PML-IRIS (n = 23; P < 0.0001, Kruskal-Wallis) for binding to VP1L55F and NAT vs. NAT-
PML-IRIS (n = 35; P = 0.0034, Kruskal-Wallis) for binding to VP1S269F. (E) Relative binding of 
serum from patients with natalizumab-associated PML to VP1 variants in comparison to 
VP1MAD1 represented as heat map. Binding efficiency to VP1 variants is illustrated by color 
gradient. Data were normalized as in (D).  
 
 
 
 
 
 
 
 
 
 
 
 Fig.2. Immune reconstitution in natalizumab-associated PML enhances intrathecal 
antibody response against VP1 variants. (A) CSF antibody responses of natalizumab-
associated PML patients (NAT-PML) and PML-IRIS patients (NAT-PML-IRIS) to VP1MAD1 
pentamers, depicted in AU (Mean ± SEM). Statistically significant P value is shown (n = 22; P = 
0.0022, Mann-Whitney U test). (B) Relative binding of CSF from each individual at diagnosis of 
PML or onset of PML-IRIS to VP1 variants in comparison to VP1MAD1 (Mean ± SEM). Data 
from each patient was normalized to its corresponding recognition to VP1MAD1 set as 100% 
binding (red dotted line). Statistically significant P value is shown for binding to VP1L55F (n = 22; 
P = 0.0106, Mann-Whitney U test). (C) Intrathecal antibody production against VP1 variants in 
PML and PML-IRIS was determined by calculation of a JCPyV variant-specific CSF/serum 
antibody index (CAI VP1JCPyV), which accounts for VP1-specific antibody levels in serum and 
CSF normalized to total albumin and total IgG CSF/serum ratio. A CSF/serum JCPyV variant-
specific antibody index >1.5 (red dotted line) was considered as evidence for intrathecal antibody 
synthesis. Statistically significant P values are shown for CAI VP1MAD1 (n = 22; P = 0.0081, 
Mann-Whitney U test), for CAI VP1WT3 (n = 22; P = 0.0061, Mann-Whitney U test), for CAI 
VP1L55F (n = 22; P = 0.0103, Mann-Whitney U test), for CAI VP1S267F (n = 22; P = 0.0159, 
Mann-Whitney U test) and for CAI VP1S269F (n = 22; P = 0.024, Mann-Whitney U test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
Fig.3. Human-derived monoclonal antibodies against JCPyV VP1 show distinct binding 
characteristics with respect to their affinity and cross-reactivity against BKV VP1. Human-
derived JCPyV VP1-specific monoclonal antibodies were recombinantly cloned from HD and 
NAT-PML-IRIS and characterized with respect to their binding properties. (A) Example of a 
high affinity JC VLP-specific antibody (98D3) targeting a conformational epitope, (B) example 
of a JC/BK VLP-cross-reactive antibody (44F6B) targeting a conformational epitope, and (C) 
example of a JC/BK VLP-cross-reactive antibody (11G6) targeting a linear epitope. Affinity and 
BKPyV-cross-reactivity was determined by EC50 in a serial dilution of a JC/BK VLP ELISA. 
ELISA of native and denatured JC VLP as well as Western Blot of JCPyV VP1 and BKPyV VP1 
were used to characterize recognition of linear or conformational epitope. 
 
 
 
 
 
                        
Fig.4. Identification of neutralizing JCPyV-specific human monoclonal antibodies. (A) 
Neutralization assay using JCPyVMAD4 on SVG-A cells. An appropriate dilution of the 
JCPyVMAD4 strain was incubated for 1 h in the absence or presence of the human monoclonal 
antibodies or isotype control at 50 µg/ml. Infected cells were detected by staining with a mouse 
anti-JCPyV VP1 (green) 72 h after infection. Nuclei were counterstained with DAPI (blue). Scale 
bars, 50 µm. Representative images illustrating neutralization capacity of antibodies belonging to 
the different categories are shown. (B) Binding affinities represented as EC50 value of HD- (left 
graph) and NAT-PML-IRIS-derived (right graph) JCPyV VP1-specific monoclonal antibodies 
against JC and BK VLP. Antibodies were classified as non-neutralizing (blue) or neutralizing 
(green). 
  
 
 
               
Fig.5. Human monoclonal antibodies display diverse binding profiles to JCV VP1 variants. 
Relative binding of NAT-PML-IRIS-derived monoclonal antibodies to VP1 variants in 
comparison to VP1MAD1 depicted as heat map (A) or scatter plot (Mean ± SEM) (B). Data of each 
antibody was normalized to its corresponding recognition to VP1MAD1 set as 100% binding (red 
dotted line in B). The antibodies were arranged according to their affinities for JC VLP and 
JCPyV neutralization capacity as well as BKPyV cross-reactivity are indicated. In (B) grey filled 
circles represent individual monoclonal antibodies and red filled circles reflect serum antibody 
responses of the NAT-PML-IRIS patient, from whom the antibodies were cloned. (C) Relative 
binding of different HD-derived monoclonal antibodies to VP1 variants in comparison to 
VP1MAD1 represented as heat map. Binding efficiency to VP1 variants is illustrated with a color 
gradient. nd = not determined 
 
                                
Fig.6. Phylogeny of IGH sequences of NAT-PML-IRIS patient-derived monoclonal 
antibodies as inferred by maximum parsimony. The branch length represents the amount of 
evolutionary divergence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
Table 1. Demographic data of patients and controls. Age and duration of natalizumab 
treatment are shown for natalizumab-treated multiple sclerosis patients (NAT), natalizumab-
associated PML patients (NAT-PML), natalizumab-associated PML-IRIS patients (NAT-PML-
IRIS) and healthy donors (HD). No statistically significant differences in age, female to male 
ratio and duration of natalizumab treatment were detected between the groups. SD = standard 
deviation. 
 NAT NAT-PML NAT-PML-
IRIS 
HD 
Number (n) 28 15 8 30 
Mean age (years ± SD) 37.6 ± 9.2 38.1 ± 8.3 42.0 ± 6.6 33.9 ± 7.5 
Range of age (years) 19-53 23-55 32-55 25-49 
Female to male ratio 1.8 2.0 1.7 1.5 
Mean duration of NAT treatment   
     (months ± SD) 
42.9 ± 22.0 51.1 ± 16.3 49.8 ± 11.3  – 
Range of treatment duration  
     (months) 
3-86 14-81 35-72 – 
 
 
 
 
 
Table 2. IGH gene usage of NAT-PML-IRIS patient-derived monoclonal antibodies. The 
germline usage for V-,D- and J-segment of IGH genes defined using the IMGT database and the 
number of amino acids in  the CDR3 region as well as amino acid  mutations as compared to the 
germline sequence are shown. IGH = immunoglobulin heavy chain; mAb = monoclonal 
antibody; VH = V-segment heavy chain; DH = D-segment heavy chain; JH = J-segment heavy 
chain; CDR3 = complementarity determining region 3; aa = amino acids. 
mAb VH DH JH CDR3 length aa mutations 
98D3 3-30*14 5-5*01 4-1*02 16 13/96 
43E8 3-30*04 3-22*01 4-1*02 14 19/95 
105C7 3-23*04 2-15*01 4-1*02 19 14/96 
45E10 3-23*04 2-15*01 4-1*02 19 13/96 
29B1 3-23*04 3-22*01 4-1*02 17 17/96 
26A3 3-23*04 3-3*02 6-1*02 17 13/96 
58C7 3-11*01 6-13*01 4-1*02 16 10/96 
47B11 3-11*01 6-13*01 4-1*02 16 5/96 
56A8 3-21*01 1-1*01 4-1*02 11 3/96 
27C2 3-21*01 1-1*01 4-1*02 11 8/96 
72F7 3-48*03 3-3*01 6-1*02 21 5/96 
59A7 3-48*03 5-5*01 4-1*01 16 4/96 
57D4 3-9*01 4-17*01 6-1*02 14 7/96 
105A6 3-9*01 5-5*01 6-1*02 14 2/96 
72F10 3-9*01 5-12*01 4-1*02 14 10/96 
27C11 4-4*02 1-14*01 6-1*02 20 5/96 
50H4 4-4*02 1-14*01 6-1*02 20 6/96 
7J3 4-30.4*01 3-10*01 6-1*02 20 3/97 
98H1 4-31*03 3-22*01 6-1*02 21 11/97 
53B11 5-51*01 1-26*01 4-1*02 13 3/96 
 
 
 
